ICON plc — FY2014 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2014. This is an annual report, not a standalone fourth-quarter filing; the supplied text does not provide Q4-only results. Financial statements are in U.S. dollars and prepared under U.S. GAAP.
Business context
ICON is an Ireland-domiciled global contract research organization (CRO), providing outsourced clinical development and related services to pharmaceutical, biotechnology and medical-device companies. At year-end it had approximately 10,600 employees across 81 locations in 38 countries. FY2014 net revenue mix was 40.3% U.S., 48.8% Europe and 10.9% rest of world.
Key financial metrics
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Gross revenue | $2,030.3 million | $1,784.3 million | +13.8% |
| Net revenue | $1,503.3 million | $1,336.1 million | +12.5% |
| Operating income | $202.4 million | $121.2 million | +67.0% |
| Operating margin | 13.4% | 9.1% | +4.3 percentage points |
| Operating income excluding restructuring and other items | $211.1 million | $130.2 million | +62.2% |
| Adjusted operating margin excluding those items | 14.0% | 9.7% | +4.3 percentage points |
| Net income | $172.5 million | $102.8 million | +67.8% |
| Diluted EPS | $2.73 | $1.65 | +65.5% |
| Operating cash flow | $169.9 million | $221.2 million | −23.2% |
Net income margin was approximately 11.5% of net revenue. Reimbursable client expenses of $527.0 million are deducted from gross revenue to calculate net revenue, which management uses as its principal revenue-growth measure. The filing reports no separate gross-profit figure.
Year-end cash and cash equivalents were $118.9 million and short-term investments were $97.1 million, for combined cash and investments of $216.0 million, down from $320.8 million in 2013. Working capital was $281.1 million, versus $352.3 million. Total assets were $1,528.9 million and shareholders’ equity was $950.2 million. The filing does not present a funded-debt balance in the supplied financial statements. A $100 million five-year revolving credit facility was available and undrawn at year-end.
Capital expenditures were $32.8 million. Investing cash outflow was $112.3 million and financing cash outflow was $116.4 million, primarily reflecting the share repurchase program. Days revenue outstanding rose to 40 days from 32 days, a working-capital headwind. The effective tax rate was 14.9%, unchanged from 2013.
Material changes versus FY2013
- Net revenue growth was 12.5%, compared with 19.8% in 2013. Management attributed 2014 growth to strategic client partnerships, the Aptiv Solutions acquisition and the full-year contribution from the 2013 Cross Country Healthcare clinical-trials-services acquisition.
- The five strategic relationships generated $771.2 million of net revenue, up from $670.7 million. One client accounted for 31% of net revenue, compared with 26% in 2013; the top five clients together represented 53% in both years.
- Direct costs declined to 60.1% of net revenue from 63.3%; SG&A declined to 22.4% from 23.5%. Management cited operating leverage, prior investment supporting partnership work and cost efficiencies.
- Operating cash flow fell by $51.3 million. Management cited higher days revenue outstanding and changes in contract-related working capital, including lower payments on account.
- Cash and investments fell by $104.8 million, reflecting acquisition spending, share repurchases and other cash uses. ICON repurchased 2.64 million shares for approximately $140.0 million; year-end shares outstanding were 60.1 million, versus 61.6 million.
- Foreign-currency translation reduced comprehensive income: the currency translation adjustment was a loss of $45.0 million, and accumulated other comprehensive income moved from $2.0 million to a loss of $37.6 million.
Outlook, commentary, risks and unusual items
- Management expected to spend approximately $47.5 million over the following 12 months on IT, facility expansion and new offices. It believed foreseeable needs could be funded from operating cash flow, existing balances and available facilities; this is a management expectation, not a formal earnings forecast.
- Backlog was approximately $3.6 billion at December 31, 2014, versus $3.1 billion a year earlier. ICON cautioned that backlog may be delayed or cancelled and is not necessarily predictive of future revenue.
- The company acquired Aptiv Solutions in May 2014 for $143.5 million cash consideration, including specified payments made on its behalf; the acquisition added adaptive-trial, medical-device and related capabilities. On February 27, 2015, after year-end, it acquired MediMedia Pharma Solutions for $120.0 million cash.
- FY2014 restructuring charges were $8.8 million: $5.6 million of asset impairments and $3.2 million for an onerous lease related to the Manchester facility after closure of European Phase I services. The remaining lease provision was expected to be paid through 2024.
- Customer concentration is material, particularly the largest client at 31% of net revenue. Other principal risks include client cancellations, fixed-fee contract cost overruns, competition and strategic-partnership retention, patient and investigator recruitment, staff retention, regulatory compliance, data privacy and cybersecurity, foreign exchange, and acquisition integration.
- ICON reported no litigation expected to have a material adverse effect and no goodwill impairment in 2014. It paid no cash dividends and did not expect to do so in the foreseeable future.
- KPMG issued unqualified opinions on the consolidated financial statements and internal control over financial reporting. Management also concluded disclosure controls were effective at year-end.
Important facts for investors to verify
- Whether growth and operating-margin gains persist after separating organic performance, Aptiv and other acquisition contributions, and the effects of Ireland-based transfer pricing.
- The largest customer’s 31% revenue share, strategic-partnership renewal and scope, and the extent to which client concentration changes.
- Cash conversion and working-capital trends, particularly the increase in days revenue outstanding and the movement in unbilled revenue and customer payments on account.
- Aptiv integration and returns, final purchase-accounting estimates, and the subsequent MediMedia acquisition’s funding and performance.
- The quality and timing of backlog conversion, given the filing’s explicit cancellation and delay caveat.
- Tax exposures: unrecognized tax benefits were $23.2 million at year-end, including $14.5 million associated with acquired tax positions; tax audits and loss-carryforward limitations may affect future results.
- Share repurchases, dilution from equity awards, and the undrawn $100 million revolving facility; confirm subsequent utilization and capital-allocation decisions.